title: [China expert consensus on the management of dyslipidemia in postmenopausal patients with early-stage breast cancer].
abstract: Estrogen has an impact on the type of lipoproteins and the blood lipid levels, thus protecting the cardiovascular system. Postmenopausal breast cancer patients suffer a significant decrease in estrogen levels due to both physiological changes and the use of drugs, and thus have a higher risk of atherosclerotic cardiovascular diseases. Therefore, strict lipid management is required for postmenopausal breast cancer patients receiving endocrine therapy. However, no guidelines have been developed in terms of lipid management and intervention for postmenopausal breast cancer patients. The Chinese expert group of multidisciplinary management of dyslipidemia in breast cancer patients with endocrine therapy, after deep investigation into the management of dyslipidemia in postmenopausal patients with early-stage breast cancer, has developed the China Expert Consensus on Dyslipidemia Management in Postmenopausal Patients with Early-stage Breast Cancer. The Consensus clearly defines the goals and measures of interventions for dyslipidemia, hoping to effectively reduce the risk of atherosclerotic cardiovascular disease in postmenopausal breast cancer patients and further improve the long-term survival of the patients.
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D050197:Atherosclerosis / Q000517:prevention & control; D001943:Breast Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D002318:Cardiovascular Diseases / Q000517:prevention & control; D002681:China; D032921:Consensus; D050171:Dyslipidemias / Q000628:therapy*; D004967:Estrogens / Q000097:blood*; D005260:Female; D006801:Humans; D008055:Lipids / Q000097:blood; D017698:Postmenopause / Q000097:blood*
chemical_list: D018931:Antineoplastic Agents, Hormonal; D004967:Estrogens; D008055:Lipids
keywords: Breast neoplasms; Dyslipidemias; Expert consensus; Hormonal therapy; Postmenopause